Generated by AI
EyePoint, Inc. Common Stock represents equity in EyePoint, Inc., a biopharmaceutical company focused on developing and commercializing therapies for serious retinal diseases. The company’s current portfolio centers on ophthalmology products and sustained-release drug delivery technologies designed to treat eye disorders and improve the management of retinal conditions. Its marketed and development-stage programs address areas such as retinal vascular disease, diabetic macular edema, and other eye diseases, using proprietary platforms that support localized, long-acting treatment delivery. EyePoint, Inc. serves the specialized eye-care market, working with healthcare providers and the broader ophthalmic industry through products and pipeline assets that target chronic retinal conditions. Headquartered in Watertown, Massachusetts, the company is positioned within the life sciences sector as a developer of therapies and drug-delivery systems for ophthalmic use.
Website480 Pleasant Street
Watertown, MA, 02472
United States
The latest articles about EYPT.
Summary of Nov 18's posts. Generated by AI.
Summary of Oct 22's posts. Generated by AI.
Summary of Nov 17's posts. Generated by AI.
Summary of Nov 12's posts. Generated by AI.
Investors talking about EYPT also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.